NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01. Changes in Registrant’s Certifying Accountant.
As previously disclosed in the Nemaura Medical Inc. (the “Company”) Current Report on Form 8-K filed on August 6, 2018 (the “Initial Form 8-K”), the Audit Committee of the Company dismissed Crowe LLP (formerly known was Crowe Horwath LLP, “Crowe”), as its independent registered public accountant.
In accordance with Item 304(a)(3) of Regulation S-K, we furnished Crowe with a copy of the Initial Form 8-K on August 6, 2018, providing Crowe with the opportunity to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made by the Company herein in response to Item 304(a) of Regulation S-K as the same pertains to Crowe and, if not, stating the respect in which it does not agree. The Company is filing this Current Report on Form 8-K/A to include the letter as exhibit 16.1, which letter was received on August 9, 2018.
Item 9.01 Financial Statements and Exhibits.
Letter from Crowe LLP, dated August 9, 2018
Nemaura Medical Inc. ExhibitEX-16.1 2 ex16x1.htm EXHIBIT 16.1 Exhibit 16.1 August 9,…To view the full exhibit click
About NEMAURA MEDICAL INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.